What Is Sermorelin?
Sermorelin corresponds to GHRH(1-29) - the first 29 amino acids of natural growth-hormone-releasing hormone, which is the shortest sequence that preserves the full activity of the parent 44-residue hormone. Everything essential for receptor binding and activation lives in that N-terminal fragment.
Because it is a faithful fragment of an endogenous hormone, Sermorelin is studied as a direct probe of the GHRH receptor rather than as a novel synthetic construct. It has a relatively short half-life compared with the stabilized or acylated GHRH analogs.
Studied Mechanism
Sermorelin engages the GHRH receptor on the anterior pituitary and stimulates the gland to release its own growth hormone in a pulsatile pattern, which in turn raises insulin-like growth factor 1 (IGF-1). Because it acts upstream and preserves the pituitary’s own feedback control, research frames it as working with the body’s natural release rhythm rather than overriding it with exogenous growth hormone.
- Sermorelin is GHRH(1-29), the shortest fully active GHRH fragment.
- Agonist at the pituitary GHRH receptor; drives pulsatile growth-hormone release.
- Raises IGF-1 downstream while preserving physiologic feedback.
- Shorter-acting than stabilized or acylated GHRH analogs.
Sermorelin, Tesamorelin, And CJC-1295
All three are GHRH-receptor agonists, but they differ in stability and duration. Sermorelin is the short-acting native fragment. Tesamorelin is a stabilized full-length GHRH(1-44) analog with protease resistance. CJC-1295 adds modifications (and, in its DAC form, albumin binding) for a substantially longer duration of action. Studying them side by side is a common way to examine how GHRH-analog half-life shapes the growth-hormone and IGF-1 response.
Research Context And Handling
Sermorelin research uses growth-hormone and IGF-1 measurement as primary endpoints, often in pituitary or endocrine model systems. As with any Research Use Only compound, verified identity and purity from the Certificate of Analysis, appropriate storage, and interpretation against the primary literature are essential. It is supplied strictly for laboratory research and not for human or animal use.
Research Use Only: This guide is informational and describes research-context handling of compounds intended strictly for in vitro laboratory research. Products are not for human or animal consumption, ingestion, or injection, and are not FDA-approved. Nothing here is medical, clinical, or dosing advice.
Frequently Asked Questions
What is Sermorelin?
Sermorelin is GHRH(1-29), the shortest fragment of growth-hormone-releasing hormone that retains full biological activity. It stimulates the pituitary GHRH receptor to release the body’s own growth hormone.
How is Sermorelin different from Tesamorelin and CJC-1295?
All three are GHRH-receptor agonists but differ in duration: Sermorelin is the short-acting native fragment, Tesamorelin is a stabilized GHRH(1-44) analog, and CJC-1295 is modified for a substantially longer duration of action.
What does Sermorelin do to IGF-1?
By driving pulsatile endogenous growth-hormone release, Sermorelin raises insulin-like growth factor 1 (IGF-1) downstream while preserving the pituitary’s own feedback control. It is a Research Use Only compound for in vitro laboratory research.